SEC Form 4 · accession 0001179110-18-002736
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Berkowitz
Director
Period of report
Feb 22, 2018
Accepted (ET)
Feb 23, 2018 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $77.94 | Feb 22, 2018 | A | 25,000 | A | — | Feb 22, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Vests in equal monthly installments rounded down to the nearest whole share over the 36 months following December 14, 2017, with the balance of the options vesting on the last monthly vesting date which is the third anniversary of December 14, 2017.